This little-known pharma stock can rally more than 60% in 2023, JPMorgan says

A promising treatment for acute leukemia makes Syndax Pharmaceuticals an attractive stock, JPMorgan said. Analyst Anupam Rama initiated coverage of Syndax with an overweight rating ahead of what could be significant new data on the company's cancer therapy called revumenib. "Our Overweight rating…#jpmorgan #rama #anupamrama #sndx #syndax #augment101 #michaelbloom
Source: Reuters: Health - Category: Consumer Health News Source Type: news